Eli Lilly announced the U.S. Food and Drug Administration (FDA) approval of a label expansion for Zepbound (tirzepatide) to include the four-dose single-patient use KwikPen, delivering a full month of treatment in one device.

Patients who choose self-pay through Lilly's direct-to-consumer website LillyDirect can receive all doses of Zepbound in a KwikPen or single dose vial. Prices start at $299 per month for the 2.5 mg dose. 

"As part of our commitment to supporting people living with obesity in their weight management journey, we are introducing a new option with the Zepbound KwikPen, a device trusted by patients globally and in the United States for other Lilly medicines," saidIlya Yuffa Ilya Yuffa, executive vice president and president of Lilly USA Lilly USAand Global Customer Capabilities, in the release.

The pen could serve as a more convenient and sustainable option, as it reduces the number of devices they have to use in a month to take the drug. Currently, patients use a different single-dose auto-injector device each week.

Patients can use one pen to take four weekly doses of Zepbound. The KwikPen is already used for other drugs, such as Lilly's diabetes medication Mounjaro.